ABT — Abbott Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual income statement for Abbott Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	PRESS
Standards:	USG	USG	USG	USG	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	43,075	43,653	40,109	41,950	44,328
Cost of Revenue
Gross Profit	24,585	24,570	22,190	23,306	25,145
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	34,650	35,336	33,670	35,307	36,323
Operating Profit	8,425	8,317	6,439	6,643	8,005
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,211	8,306	6,664	7,013	8,466
Provision for Income Taxes
Net Income After Taxes	7,071	6,933	5,723	13,402	6,524
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	7,071	6,933	5,723	13,402	6,524
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7,071	6,933	5,723	13,402	6,524
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.03	4.12	3.43	7.81	4
Dividends per Share